Related references
Note: Only part of the references are listed.Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy
Nicholas T. Funderburg et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
CIRCULATION (2014)
Rosuvastatin Treatment Reduces Markers of Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy
Nicholas T. Funderburg et al.
CLINICAL INFECTIOUS DISEASES (2014)
Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients
Leonardo Calza et al.
HIV CLINICAL TRIALS (2014)
Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment
Allan R. Tenorio et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Harvey D. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effect of Statin Therapy in Reducing the Risk of Serious Non-AIDS-Defining Events and Nonaccidental Death
E. T. Overton et al.
CLINICAL INFECTIOUS DISEASES (2013)
Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study
Line D. Rasmussen et al.
PLOS ONE (2013)
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor
Randa Bittar et al.
AIDS (2012)
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome
Nicholas T. Funderburg et al.
BLOOD (2012)
Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load
Stephane De Wit et al.
AIDS (2011)
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection
Carl J. Fichtenbaum et al.
AIDS (2011)
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons
Chun Chao et al.
AIDS (2011)
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors
Elisabeth Aslangul et al.
AIDS (2011)
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients
Sudershan Singh et al.
CLINICAL INFECTIOUS DISEASES (2011)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
Anuradha Ganesan et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
Netanya G. Sandler et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial
Elisabeth Aslangul et al.
AIDS (2010)
Induction of Endothelial Nitric Oxide Synthase, SIRT1, and Catalase by Statins Inhibits Endothelial Senescence Through the Akt Pathway
Hidetaka Ota et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells
Michihisa Jougasaki et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives
Qian Zhou et al.
CIRCULATION JOURNAL (2010)
Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
Jerome Cros et al.
IMMUNITY (2010)
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
LANCET (2010)
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study
Carl Grunfeld et al.
AIDS (2009)
Statins for the Prevention and Treatment of Infections A Systematic Review and Meta-analysis
Imad M. Tleyjeh et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Antiretroviral and Statin Drug-Drug Interactions
Gretchen M. Ray
CARDIOLOGY IN REVIEW (2009)
Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima-Media Thickness in HIV-Infected Patients Receiving Antiretroviral Therapy
Allison C. Ross et al.
CLINICAL INFECTIOUS DISEASES (2009)
Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction
Virginia A. Triant et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Paul M. Ridker et al.
LANCET (2009)
Immunomodulatory and Anti-Inflammatory Activities of Statins
Emilia Mira et al.
Endocrine Metabolic & Immune Disorders-Drug Targets (2009)
Preadmission Use of Statins and Outcomes After Hospitalization With Pneumonia - Population-Based Cohort Study of 29 900 Patients
Reimar W. Thomsen et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers
Jennifer J. Kiser et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin
Anthony J. Busti et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2008)
Confronting an influenza pandemic with inexpensive generic agents: can it be done?
David S. Fedson
LANCET INFECTIOUS DISEASES (2008)
Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication
Tohti Amet et al.
MICROBES AND INFECTION (2008)
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
Lewis H. Kuller et al.
PLOS MEDICINE (2008)
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
Virginia A. Triant et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy
Franck Boccara et al.
AIDS (2006)
Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects
H Yasuda et al.
KIDNEY INTERNATIONAL (2006)
Role of tissue factor in hemostasis and thrombosis
N Mackman
BLOOD CELLS MOLECULES AND DISEASES (2006)
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
E Negredo et al.
AIDS (2006)
Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms
MK Jain et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Anti-angiogenic and anti-inflammatory effects of statins:: Relevance to anti-cancer therapy
J Dulak et al.
CURRENT CANCER DRUG TARGETS (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Statins and HIV: Beyond the metabolic and cardiovascular benefit
VF Corrales-Medina et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial
S Stender et al.
DIABETES OBESITY & METABOLISM (2005)
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin - Results of AIDS clinical trials group 5108 study
JG Gerber et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia
L Calza et al.
AIDS (2005)
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study
TT Brown et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Statins inhibit HIV-1 infection by down-regulating Rho activity
G del Real et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study
TE Strandberg et al.
CLINICAL THERAPEUTICS (2004)
Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1
JF Giguère et al.
JOURNAL OF VIROLOGY (2004)
Early intervention with atorvastatin modulates Th1/Th2 imbalance in patients with acute coronary syndrome: From bedside to bench
K Shimada et al.
CIRCULATION (2004)
Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy.: Aquitaine Cohort, France, 1999-2001
F Bonnet et al.
HIV MEDICINE (2004)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors
JA Tobert
NATURE REVIEWS DRUG DISCOVERY (2003)
Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
N Friis-Moller et al.
AIDS (2003)
Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors
S Narayan et al.
HIV CLINICAL TRIALS (2003)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
